FMP

FMP

Enter

INFI - Infinity Pharmaceuti...

photo-url-https://images.financialmodelingprep.com/symbol/INFI.png

Infinity Pharmaceuticals, Inc.

INFI

NASDAQ

Inactive Equity

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

0.008 USD

-0.0088 (-110%)

INFI Financial Statements

Year

2022

2021

2020

2019

Total Revenue

2.59M

1.86M

1.72M

3.05M

Cost of Revenue

1.56M

1.12M

1.04M

7.31M

Gross Profit

1.03M

738k

682k

-4.26M

Operating Expenses

45.87M

45.82M

39.18M

41.41M

Research and Development

32.41M

31.65M

26.76M

27.12M

Selling, General & Administrative Expenses

13.46M

14.17M

12.42M

14.29M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

13.46M

14.17M

12.42M

14.29M

Other Expenses

1.56M

1.12M

1.04M

7.31M

Operating Income

-44.84M

-45.08M

-38.5M

-45.66M

Total Other Income/Expenses Net

475k

-179k

-2M

-1.45M

Income Before Tax

-44.37M

-45.26M

-40.49M

-47.11M

Income Tax

-1.11M

180k

2.44M

-54k

Net Income

-43.26M

-45.44M

-42.94M

-47.06M

Basic EPS

-0.48

-0.53

-0.72

-0.83

EPS Diluted

-0.48

-0.53

-0.72

-0.83

Basic Average Shares

89.25M

85.6M

59.86M

56.98M

Diluted Average Shares

89.25M

85.6M

59.86M

56.98M

EBITDA

-44.84M

-44.6M

-38.01M

-45.66M

Retained Earning Schedule

Year

2022

2021

2020

2019

Retained Earnings (Previous Year)

-811.58M

-766.32M

-725.83M

-678.77M

Net Income

-43.26M

-45.44M

-42.94M

-47.06M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-855.95M

-811.58M

-766.32M

-725.83M

Other Distributions

-44.37M

-45.26M

-40.49M

-47.06M

PPE Schedule

Year

2022

2021

2020

2019

Gross PPE

800k

2.31M

3.13M

2.19M

Annual Depreciation

458k

480k

483k

219k

Capital Expenditure

-17k

-11k

-43k

-2.33M

Net PPE

359k

1.84M

2.69M

4.29M

Intangible and Goodwill Schedule

Year

2022

2021

2020

2019

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep